Amlodipine FDA Approval History

How Amlodipine Reached the U.S. Market

Amlodipine besylate was developed by Pfizer as a long-acting dihydropyridine calcium channel blocker with a half-life of 30 to 50 hours, far longer than first-generation agents like nifedipine. The FDA accepted Pfizer's New Drug Application (NDA 19-787) and granted approval on July 31, 1992, for two indications: hypertension and chronic stable angina pectoris [1].

Pre-Approval Clinical Program

Pfizer's registration program included over 1,700 patients in controlled trials comparing amlodipine to placebo and active comparators. Dose-response studies established the 5 mg and 10 mg tablets as the primary therapeutic range, with 2.5 mg reserved for smaller patients and those with hepatic impairment [1]. Blood pressure reductions averaged 12 to 15 mmHg systolic and 7 to 10 mmHg diastolic at the 5 mg dose in key trials submitted to the FDA [2].

Why the Besylate Salt Matters

Amlodipine is formulated as the besylate (benzenesulfonate) salt. This salt form gives the drug high oral bioavailability (64 to 90%) and slow, predictable absorption that produces steady-state plasma levels within 7 to 8 days of once-daily dosing [2]. The pharmacokinetic profile was a key differentiator in the NDA review: unlike short-acting calcium channel blockers, amlodipine did not produce reflex tachycardia or abrupt blood pressure swings. The FDA's medical review noted this as a distinct safety advantage [1].

Early Label and Dosing

The original 1992 label recommended a starting dose of 5 mg once daily, with titration to 10 mg based on clinical response. For elderly patients and those with hepatic dysfunction, a 2.5 mg starting dose was specified. No renal dose adjustment was required because amlodipine is extensively hepatically metabolized, and only 10% of the parent compound appears in urine [2].

Supplemental Approvals and Label Expansions

The amlodipine label has been revised more than a dozen times since 1992. Several of these revisions added new clinical data or indications that broadened the drug's utility.

Vasospastic Angina Indication (1994)

In 1994, the FDA approved a supplemental NDA adding vasospastic (Prinzmetal or variant) angina as a third indication. The supporting data came from controlled trials in patients with angiographically confirmed coronary vasospasm, where amlodipine reduced anginal episodes by approximately 50% compared to placebo [1].

Coronary Artery Disease Risk Reduction

The CAMELOT trial (Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis, published 2004) provided evidence that amlodipine 10 mg reduced cardiovascular events in patients with angiographically documented coronary artery disease (CAD). The study enrolled 1,991 patients and showed a 31% relative reduction in the composite of cardiovascular death, nonfatal MI, resuscitated cardiac arrest, coronary revascularization, hospitalization for angina, and hospitalization for heart failure compared to placebo (P=0.003) [3]. This data supported label language regarding use in patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%.

Pediatric Labeling

A supplemental approval in 2004 added pharmacokinetic and efficacy data for pediatric patients aged 6 to 17 years with hypertension. The recommended pediatric dose is 2.5 mg to 5 mg once daily [1]. Doses above 5 mg have not been studied in this population.

The ASCOT-BPLA Trial and Its Regulatory Impact

The Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Lowering Arm (ASCOT-BPLA) remains the landmark trial shaping how clinicians and regulators view amlodipine's cardiovascular benefit.

Study Design and Population

ASCOT-BPLA randomized 19,257 hypertensive patients with at least three additional cardiovascular risk factors to either amlodipine-based therapy (adding perindopril as needed) or atenolol-based therapy (adding bendroflumethiazide as needed). The trial was stopped early at a median follow-up of 5.5 years because of significant differences favoring the amlodipine arm [4].

Key Outcomes

The amlodipine-based regimen reduced all-cause mortality by 11% (P=0.025), stroke by 23% (P=0.0003), and total cardiovascular events and procedures by 16% (P <0.0001) compared to the atenolol-based regimen [4]. These results contributed to a shift in international guidelines away from beta-blockers as first-line antihypertensives for uncomplicated hypertension and strengthened amlodipine's position in formularies globally.

Regulatory Consequences

While ASCOT-BPLA did not trigger a formal FDA supplemental indication, it influenced the drug's label in the "Clinical Studies" section and shaped the AHA/ACC guideline recommendations that the FDA cross-references. The 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults lists calcium channel blockers (including amlodipine) as a first-line option for all adult hypertensive patients, alongside thiazide diuretics, ACE inhibitors, and ARBs [5].

Generic Entry and Market Dynamics

Pfizer's compound patent on amlodipine besylate (U.S. Patent 4,572,909) expired in September 2006. Pediatric exclusivity extended Norvasc's market protection by an additional six months.

The 2007 Generic Wave

The first generic amlodipine besylate products received ANDA approvals in March 2007. Mylan, Watson Pharmaceuticals, and Apotex were among the earliest entrants. By 2009, more than ten manufacturers held active ANDAs for amlodipine besylate tablets [6].

Pricing Impact

Brand-name Norvasc 5 mg was priced at approximately $4.50 per tablet in 2006. Generic competition reduced the cost to below $0.10 per tablet within three years. As of 2024, a 30-day supply of generic amlodipine 5 mg costs $3 to $8 at most U.S. Pharmacies, making it one of the least expensive branded-to-generic conversions in cardiovascular medicine [6].

Alternative Salts

In 2006, Azor Pharma (later acquired by Daiichi Sankyo) received approval for amlodipine as the maleate salt, though this formulation never gained significant U.S. Market share. The besylate salt remains the standard formulation across all major generic manufacturers.

Post-Market Safety Surveillance

More than three decades of post-market data make amlodipine one of the most extensively monitored cardiovascular drugs in the FDA Adverse Event Reporting System (FAERS).

Common Adverse Events

The most frequently reported adverse events in FAERS and in the current label include peripheral edema (occurring in up to 10.8% of patients on 10 mg), dizziness (3.4%), flushing (2.6%), and palpitations (1.4%) [2]. Peripheral edema is dose-dependent and results from arteriolar dilation without corresponding venodilation.

Serious Safety Signals Investigated

Two post-market safety concerns received formal FDA attention:

Gingival hyperplasia. Case reports accumulated through the 1990s describing drug-induced gingival overgrowth. The FDA added gingival hyperplasia to the "Post-Marketing Experience" section of the label. Incidence is estimated at 1 to 3% in long-term users and is reversible upon discontinuation [7].

Short-acting CCB controversy. In 1995, a widely cited meta-analysis by Psaty et al. (JAMA, 1995) raised concerns about increased MI risk with short-acting calcium channel blockers. Amlodipine, as a long-acting agent, was not implicated. The FDA reviewed the data and concluded that long-acting dihydropyridines, including amlodipine, did not carry the same risk signal. The ALLHAT trial (N=33,357) subsequently confirmed that amlodipine-based therapy produced cardiovascular outcomes comparable to chlorthalidone and lisinopril, with no excess coronary risk [8].

FAERS Reporting Trends

Between 2004 and 2023, FAERS logged over 45,000 adverse event reports mentioning amlodipine as a suspect drug. The most common serious reports involve peripheral edema, hypotension, and acute kidney injury (often in the context of co-administered nephrotoxic drugs). No new safety signals have triggered formal FDA regulatory action since the gingival hyperplasia label update [9].

Current FDA Label: Key Sections

The amlodipine besylate prescribing information (last revised 2023) spans 15 pages and contains specific language worth highlighting for prescribers.

Indications and Usage

Three labeled indications remain in effect: (1) hypertension, alone or in combination with other antihypertensives; (2) chronic stable angina, alone or in combination with other antianginals; and (3) confirmed or suspected vasospastic angina [2]. The CAD risk-reduction language appears in the Clinical Studies section rather than as a discrete indication.

Black Box Warning Status

Amlodipine carries no black box warning. This distinguishes it from some other cardiovascular drugs (e.g., certain beta-blockers with abrupt-withdrawal warnings) and contributes to its favorable prescribing profile.

Drug Interactions on the Label

The current label notes a pharmacokinetic interaction with simvastatin: co-administration increases simvastatin exposure, and the simvastatin dose should not exceed 20 mg daily when used with amlodipine. Co-administration with cyclosporine or tacrolimus may increase levels of those immunosuppressants. No clinically significant interaction with digoxin, warfarin, or cimetidine was identified in dedicated studies [2].

Hepatic Impairment Guidance

Because amlodipine is extensively metabolized by the liver, patients with severe hepatic impairment show increased AUC by approximately 40 to 60%. The label recommends starting at 2.5 mg and titrating slowly [2].

Combination Products Containing Amlodipine

The FDA has approved several fixed-dose combination products that include amlodipine as a component.

Amlodipine/Atorvastatin (Caduet)

Approved in 2004, Caduet combines amlodipine (2.5 to 10 mg) with atorvastatin (10 to 80 mg) in a single tablet. The rationale was addressing both hypertension and dyslipidemia in patients with overlapping cardiovascular risk factors [10].

Amlodipine/Benazepril (Lotrel)

Lotrel, approved in 1995, pairs amlodipine with the ACE inhibitor benazepril. This combination targets the edema side effect: ACE inhibitors cause venodilation that partially offsets the arteriolar dilation from amlodipine, reducing peripheral edema rates [10].

Amlodipine/Olmesartan (Azor) and Triple Combinations

Azor (amlodipine/olmesartan) received approval in 2007. A triple combination of amlodipine, olmesartan, and hydrochlorothiazide (Tribenzor) followed in 2010. These products reflect the guideline-endorsed strategy of using complementary antihypertensive mechanisms in a single pill to improve adherence [10].

Regulatory Status Outside the United States

Amlodipine holds marketing authorizations in over 100 countries. The European Medicines Agency (EMA) has not issued a centralized marketing authorization for amlodipine (it predates the centralized procedure), but national authorizations exist across all EU member states. The WHO includes amlodipine on its Model List of Essential Medicines, most recently in the 2023 edition, at the 5 mg strength [11].

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved amlodipine besylate in 1993, one year after the U.S. Approval. The drug's adoption was particularly rapid in Japan, where it became the most prescribed antihypertensive by the early 2000s.

What the Approval History Means for Prescribers Today

Amlodipine's 30-plus-year regulatory track record provides an unusually complete dataset for clinical decision-making. The drug has survived multiple safety controversies that affected the broader calcium channel blocker class, been validated in trials enrolling over 50,000 patients collectively, and maintained its first-line guideline status through three major ACC/AHA hypertension guideline revisions. Generic amlodipine besylate 5 mg tablets cost under $0.10 per unit, placing effective blood pressure control within reach for virtually all insured and many uninsured patients.

The ACC/AHA 2017 guideline states: "Thiazide diuretics, CCBs, ACE inhibitors, and ARBs are recommended as first-line agents" for stage 1 hypertension (BP 130-139/80-89 mmHg) with a 10-year ASCVD risk of 10% or greater [5]. For Black adults, the same guideline specifically recommends initial therapy with a thiazide-type diuretic or CCB, a recommendation built partly on ALLHAT subgroup data showing superior stroke prevention with amlodipine versus lisinopril in Black participants (RR 0.60, 95% CI 0.46 to 0.79) [8].